Drug intelligence / Profile preview

NV01-A03

Development stage: Unknown
Lead developer: Neuroventi
Modality: Small Molecules
Administration: Oral

Overview

NV01-A03 is a small molecule therapeutic candidate being developed by Neuroventi for the treatment of depression and pain. It is a repurposed drug that acts as a dual modulator of imidazoline receptors and alpha-adrenergic receptors. The drug is currently in Phase 2 clinical development, with the company pursuing a global strategy including scientific advisory from the European Medicines Agency (EMA). The mechanism involves targeting neuroinflammation and neurotransmitter balance associated with mood disorders and chronic pain.

Targets

ADRA1A (α1A)

Beyond the preview

Go deeper on NV01-A03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NV01-A03.

Explore the full profile